Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.
Maria Orietta Borghi,Asmaa Beltagy,Emirena Garrafa,Daniele Curreli,Germana Cecchini,Caterina Bodio,Claudia Grossi,Simonetta Blengino,Angela Tincani,Franco Franceschini,Laura Andreoli,Maria Grazia Lazzaroni,Silvia Piantoni,Stefania Masneri,Francesca Crisafulli,Duilio Brugnoni,Maria Lorenza Muiesan,Massimo Salvetti,Gianfranco Parati,Erminio Torresani,Michael Mahler,Francesca Heilbron,Francesca Pregnolato,Martino F. Pengo,Francesco Tedesco,Nicola Pozzi,Pier Luigi Meroni +26 more
Reads0
Chats0
TLDR
APL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome, which shows a low prevalence and is not associated with major thrombotic events.Abstract:
Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPLs) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI), and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β2GPI antibodies was not reported. Objective To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β2GPI antibodies. Methods ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events. Results Anti-β2GPI IgG/IgA/IgM was the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM was detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β2GPI nor with thrombosis. Conclusions aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.read more
Citations
More filters
Journal ArticleDOI
Innate immunity: the first line of defense against SARS-CoV-2
TL;DR: Kanneganti et al. as discussed by the authors reviewed the key role played by innate immunity in the control and immunopathology of COVID-19 and discussed innate immune processes involved in SARS-CoV-2 recognition and the resultant inflammation.
Journal ArticleDOI
COVID-19 and Cardiovascular Disease: From Bench to Bedside.
Mina K. Chung,David A. Zidar,Michael R. Bristow,Scott J. Cameron,Timothy A. Chan,Clifford V. Harding,Deborah H. Kwon,Tamanna Singh,John C. Tilton,Emily J. Tsai,Nathan R. Tucker,John Barnard,Joseph Loscalzo +12 more
TL;DR: A review of the clinical manifestations of cardiovascular involvement, potential direct SARS-CoV-2 and indirect immune response mechanisms impacting the cardiovascular system, and implications for the management of patients after recovery from acute COVID-19 infection is provided in this article.
Journal ArticleDOI
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.
Azita Hajhossein Talasaz,Parham Sadeghipour,Hessam Kakavand,Maryam Aghakouchakzadeh,Elaheh Kordzadeh-Kermani,Benjamin W. Van Tassell,Azin Gheymati,Hamid Ariannejad,Seyed Hossein Hosseini,Sepehr Jamalkhani,Michelle Sholzberg,Manuel Monreal,David Jiménez,Gregory Piazza,Sahil A. Parikh,Ajay J. Kirtane,John W. Eikelboom,Jean M. Connors,Beverley J. Hunt,Stavros Konstantinides,Mary Cushman,Jeffrey I. Weitz,Gregg W. Stone,Harlan M. Krumholz,Gregory Y.H. Lip,Samuel Z. Goldhaber,Behnood Bikdeli +26 more
TL;DR: In this paper, a variety of antithrombotic agents, doses, and durations of therapy are assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19.
Journal ArticleDOI
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system.
Maria Grazia Lazzaroni,Silvia Piantoni,Stefania Masneri,Emirena Michela Garrafa,Giuliana Martini,Angela Tincani,Laura Andreoli,Franco Franceschini +7 more
TL;DR: Coagulation dysfunction is a candidate risk factor for adverse outcomes in COVID-19 and should be carefully addressed in clinical practice.
Journal ArticleDOI
COVID-19 vasculitis and novel vasculitis mimics.
Dennis McGonagle,Dennis McGonagle,Charlie Bridgewood,Athimalaipet V Ramanan,James F. Meaney,Abdulla Watad,Abdulla Watad,Abdulla Watad +7 more
TL;DR: In this paper, the authors highlight how imaging and post-mortem findings from patients with COVID-19 indicate a novel thrombosis in the pulmonary venous territory distal to the alveolar capillary bed, a territory that normally acts as a clot filtration system, which might represent an unappreciated nidus for systemic microembolism.
References
More filters
Journal ArticleDOI
Systematic Review: Process of Forming Academic Service Partnerships to Reform Clinical Education
TL;DR: This study’s findings can provide practical guidelines to steer partnership programs within the academic and clinical bodies, with the aim of providing a collaborative partnership approach to clinical education.
Journal ArticleDOI
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
TL;DR: In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronvirus pneumonia (NCP) cases were a concern.
Journal ArticleDOI
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
Frederikus A. Klok,Marieke J. H. A. Kruip,N.J.M. van der Meer,M.S. Arbous,Diederik Gommers,K.M. Kant,F H J Kaptein,J. van Paassen,M A M Stals,Menno V. Huisman,Henrik Endeman +10 more
TL;DR: The findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophYLaxis towards high-prophylactic doses, even in the absence of randomized evidence.
Journal ArticleDOI
Clinical and immunological features of severe and moderate coronavirus disease 2019.
Guang Chen,Di Wu,Wei Guo,Yong Cao,Da Huang,Hongwu Wang,Tao Wang,Xiaoyun Zhang,Huilong Chen,Haijing Yu,Xiaoping Zhang,Minxia Zhang,Shiji Wu,Jianxin Song,Tao Chen,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +19 more
TL;DR: The SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in numbers as well as IFN-γ production, which may be of importance due to their correlation with disease severity in COVID-19.
Journal ArticleDOI
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.
Yan Zhang,Meng Xiao,Shulan Zhang,Peng Xia,Wei Cao,Wei Jiang,Huan Chen,Xin Ding,Hua Zhao,Hongmin Zhang,Chunyao Wang,Jing Zhao,Xuefeng Sun,Ran Tian,Wei Wu,Dong Wu,Jie Ma,Yu Chen,Dong Zhang,Jing Xie,Xiaowei Yan,Xiang Zhou,Zhengyin Liu,Jinglan Wang,Bin Du,Yan Qin,Peng Gao,Xuzhen Qin,Yingchun Xu,Wen Zhang,Taisheng Li,Fengchun Zhang,Yongqiang Zhao,Yongzhe Li,Shuyang Zhang +34 more
TL;DR: A 69-year-old man with Covid-19 diagnosed in January 2020 in Wuhan, China, along with two other critically ill patients with Covod-19 who were also seen in the same intensive care unit are described.
Related Papers (5)
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19.
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.
Yan Zhang,Meng Xiao,Shulan Zhang,Peng Xia,Wei Cao,Wei Jiang,Huan Chen,Xin Ding,Hua Zhao,Hongmin Zhang,Chunyao Wang,Jing Zhao,Xuefeng Sun,Ran Tian,Wei Wu,Dong Wu,Jie Ma,Yu Chen,Dong Zhang,Jing Xie,Xiaowei Yan,Xiang Zhou,Zhengyin Liu,Jinglan Wang,Bin Du,Yan Qin,Peng Gao,Xuzhen Qin,Yingchun Xu,Wen Zhang,Taisheng Li,Fengchun Zhang,Yongqiang Zhao,Yongzhe Li,Shuyang Zhang +34 more
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Paul Bastard,Paul Bastard,Paul Bastard,Lindsey B. Rosen,Qian Zhang,Eleftherios Michailidis,Hans-Heinrich Hoffmann,Yu Zhang,Karim Dorgham,Quentin Philippot,Quentin Philippot,Jérémie Rosain,Jérémie Rosain,Vivien Béziat,Vivien Béziat,Vivien Béziat,Jeremy Manry,Jeremy Manry,Elana Shaw,Liis Haljasmägi,Pärt Peterson,Lazaro Lorenzo,Lazaro Lorenzo,Lucy Bizien,Lucy Bizien,Sophie Trouillet-Assant,Kerry Dobbs,Adriana Almeida de Jesus,Alexandre Belot,Anne Kallaste,Emilie Catherinot,Yacine Tandjaoui-Lambiotte,Jérémie Le Pen,Gaspard Kerner,Gaspard Kerner,Benedetta Bigio,Yoann Seeleuthner,Yoann Seeleuthner,Rui Yang,Alexandre Bolze,András N Spaan,András N Spaan,Ottavia M. Delmonte,Michael S. Abers,Alessandro Aiuti,Giorgio Casari,Vito Lampasona,Lorenzo Piemonti,Fabio Ciceri,Kaya Bilguvar,Richard P. Lifton,Richard P. Lifton,Marc Vasse,David M. Smadja,Mélanie Migaud,Mélanie Migaud,Jérôme Hadjadj,Benjamin Terrier,Darragh Duffy,Lluis Quintana-Murci,Lluis Quintana-Murci,Diederik van de Beek,Lucie Roussel,Donald C. Vinh,Stuart G. Tangye,Stuart G. Tangye,Filomeen Haerynck,David Dalmau,Javier Martinez-Picado,Javier Martinez-Picado,Petter Brodin,Petter Brodin,Michel C. Nussenzweig,Michel C. Nussenzweig,Stéphanie Boisson-Dupuis,Stéphanie Boisson-Dupuis,Stéphanie Boisson-Dupuis,Carlos Rodríguez-Gallego,Guillaume Vogt,Trine H. Mogensen,Trine H. Mogensen,Andrew J. Oler,Jingwen Gu,Peter D. Burbelo,Jeffrey I. Cohen,Andrea Biondi,Laura Rachele Bettini,Mariella D'Angiò,Paolo Bonfanti,Patrick Rossignol,Julien Mayaux,Frédéric Rieux-Laucat,Eystein S. Husebye,Eystein S. Husebye,Eystein S. Husebye,Francesca Fusco,Matilde Valeria Ursini,Luisa Imberti,Alessandra Sottini,Simone Paghera,Eugenia Quiros-Roldan,Camillo Rossi,Riccardo Castagnoli,Daniela Montagna,Amelia Licari,Gian Luigi Marseglia,Xavier Duval,Jade Ghosn,Hgid Lab,Covid Clinicians,Covid-Storm Clinicians§,CoV-Contact Cohort§,Amsterdam Umc Covid Biobank,Amsterdam Umc Covid Biobank,Amsterdam Umc Covid Biobank,Covid Human Genetic Effort,John S. Tsang,Raphaela Goldbach-Mansky,Kai Kisand,Michail S. Lionakis,Anne Puel,Anne Puel,Anne Puel,Shen-Ying Zhang,Shen-Ying Zhang,Shen-Ying Zhang,Steven M. Holland,Guy Gorochov,Emmanuelle Jouanguy,Emmanuelle Jouanguy,Emmanuelle Jouanguy,Charles M. Rice,Aurélie Cobat,Aurélie Cobat,Aurélie Cobat,Luigi D. Notarangelo,Laurent Abel,Laurent Abel,Laurent Abel,Helen C. Su,Jean-Laurent Casanova +140 more